- BriaCell Therapeutics Corp. (BCT) is manufacturing its personalized immunotherapy, a treatment against advanced breast cancer
- Bria-OTS™ is currently undergoing quality control testing for the potential clinical trial
- Therapies intended to trigger potent immune responses against cancer in mouse models will be used
- Bria-OTS™ is an immunotherapy treatment derived from a human breast cancer cell line
- BriaCell Therapeutics Corp. (BCT) is up 3.56 per cent and is trading at $13.96 per share as of 11:52 a.m. ET
BriaCell Therapeutics Corp. (BCT) is manufacturing its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, a treatment against advanced breast cancer.
Bria-OTS™ is currently undergoing quality control testing for the potential upcoming clinical trial. It is also conducting extensive testing on immunotherapy products in compliance with a division of the FDA.
BriaCell is planning for the treatment to enter an open-label phase I/IIa clinical trial to evaluate its safety and efficacy in patients with advanced breast cancer.
BriaCell is collaborating with the National Cancer Institute (NCI) to conduct the studies. They are using their combined expertise in tumour immunology, molecular biology, and cellular therapies intended to trigger the pathways necessary to create potent immune responses against cancer in mouse models.
Bria-OTS™ is a pre-manufactured genetically engineered immunotherapy treatment derived from a human breast cancer cell line. A simple saliva test determines the HLA-type of individual patients with breast cancer who are being evaluated for possible treatment with this novel therapy.
BriaCell then anticipates treating each patient with the appropriate pre-manufactured Bria-OTS™ formulation based on the patient’s human leukocyte antigen (HLA) type, which is responsible for regulating the immune system.
Once administered to patients, Bria-OTS™ immunotherapies will attempt to trigger the patient’s immune system to recognize and eliminate cancerous cells by both activating tumour-directed white blood cells, and potentially antibody responses.
BriaCell Therapeutics Corp. (BCT) is up 3.56 per cent and is trading at $13.96 per share as of 11:52 a.m. ET.